AnaptysBio (ANAB) to discuss ANB033; posts Oct 2025 presentations

AnaptysBio, Inc. (ANAB) filed a Form 8-K announcing that on October 14, 2025 it will host a conference call to discuss ANB033 and use a slide presentation during the call.

Accepted by SEC EDGAR 10/14/2025 - 04:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AnaptysBio, Inc. (ANAB) filed a Form 8-K announcing that on October 14, 2025 it will host a conference call to discuss ANB033 and use a slide presentation during the call. The company also updated its corporate investor presentation on the same date.

Both presentations are furnished under Regulation FD as Exhibits 99.1 and 99.2 and, as stated, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference except as expressly set forth by specific reference.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AnaptysBio (ANAB) announce in this 8-K?

It will host a conference call on October 14, 2025 to discuss ANB033 and has updated its corporate investor presentation.

Which exhibits contain the presentations for ANAB?

Exhibit 99.1 is the Investor Presentation dated October 14, 2025, and Exhibit 99.2 is the Anaptys Corporate Presentation October 2025.

Are these materials considered filed with the SEC?

No. The materials in Item 7.01, including Exhibits 99.1 and 99.2, are furnished under Regulation FD and are not deemed “filed” under Section 18 of the Exchange Act.

What topic will the conference call cover?

The call will discuss ANB033 and use a slide presentation in conjunction with the discussion.

Where is AnaptysBio listed and under what ticker?

Its common stock trades on The Nasdaq Stock Market LLC under the ticker ANAB.

When were the updated materials prepared?

They are dated October 2025, with the investor presentation specifically dated October 14, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001370053false00013700532025-10-142025-10-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: October 14, 2025

(Date of earliest event reported)

ANAPTYSBIO, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-37985			20-3828755
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

10770 Wateridge Circle, Suite 210,

San Diego, CA 92121

(Address of Principal Executive Offices, and Zip Code)

(858) 362-6295

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			ANAB			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.    Regulation FD.

On October 14, 2025, AnaptysBio, Inc. (“AnaptysBio”) will host a conference call to discuss ANB033 and use a slide presentation in conjunction with the call. A copy of the presentation is filed herewith as Exhibit 99.1.

On October 14, 2025, AnaptysBio updated its corporate investor presentation, a full copy of which is attached hereto as Exhibit 99.2.

The information in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Exhibit Title or Description
99.1			AnaptysBio, Inc. Investor Presentation, dated October 14, 2025.
99.2			Anaptys Corporate Presentation October 2025.
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						AnaptysBio, Inc.
Date: October 14, 2025						By:			/s/ Dennis Mulroy
									Name: Dennis Mulroy
									Title: Chief Financial Officer